Literature DB >> 1647982

ATP-dependent reversible association of proteasomes with multiple protein components to form 26S complexes that degrade ubiquitinated proteins in human HL-60 cells.

E Orino1, K Tanaka, T Tamura, S Sone, T Ogura, A Ichihara.   

Abstract

The role of proteasomes in ubiquitin (Ub)-dependent protein degradation was studied by analyzing lysates of human promyelocytic leukemia HL-60 cells by glycerol density gradient centrifugation. High succinyl-Leu-Leu-Val-Tyr-4-methylcoumaryl-7-amide hydrolyzing activity was found in the 26S fraction, whereas the 20S fraction containing proteaomes had no activity. Addition of 0.05% sodium dodecylsulfate to the latter fraction, however, induced marked activity. The 26S, but not the 20S fraction catalyzed ATP-dependent degradation of [125I]lysozyme-Ub conjugate. Depletion from the lysate of ATP caused complete shift of the active 26S complex to the latent 20S form, whereas in the lysate prepared from ATP-depleted cells, ATP converted 20S proteasomes to 26S complexes. The immunoprecipitated 26S complexes were found to consist of proteasomes and 13-15 other proteins ranging in size from 35 to 110 kDa. We conclude that in the lysate, latent proteasomes undergo reversible, ATP-dependent association with multiple protein components to form 26S complexes that catalyze ATP-dependent degradation of Ub-protein conjugates.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1647982     DOI: 10.1016/0014-5793(91)80686-w

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  31 in total

1.  The cellular level of PR500, a protein complex related to the 19S regulatory particle of the proteasome, is regulated in response to stresses in plants.

Authors:  Z Peng; J M Staub; G Serino; S F Kwok; J Kurepa; B D Bruce; R D Vierstra; N Wei; X W Deng
Journal:  Mol Biol Cell       Date:  2001-02       Impact factor: 4.138

2.  Multiple forms of protein kinase CK2 present in leukemic cells: in vitro study of its origin by proteolysis.

Authors:  J Roig; A Krehan; D Colomer; W Pyerin; E Itarte; M Plana
Journal:  Mol Cell Biochem       Date:  1999-01       Impact factor: 3.396

3.  An ATP-stabilized inhibitor of the proteasome is a component of the 1500-kDa ubiquitin conjugate-degrading complex.

Authors:  J Driscoll; J Frydman; A L Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

4.  Mild heat stress stimulates 20S proteasome and its 11S activator in human fibroblasts undergoing aging in vitro.

Authors:  Rasmus Beedholm; Brian F C Clark; Suresh I S Rattan
Journal:  Cell Stress Chaperones       Date:  2004-03       Impact factor: 3.667

Review 5.  Regulation by proteolysis: energy-dependent proteases and their targets.

Authors:  S Gottesman; M R Maurizi
Journal:  Microbiol Rev       Date:  1992-12

6.  Global organization and function of mammalian cytosolic proteasome pools: Implications for PA28 and 19S regulatory complexes.

Authors:  Toru Shibatani; Eric J Carlson; Fredrick Larabee; Ashley L McCormack; Klaus Früh; William R Skach
Journal:  Mol Biol Cell       Date:  2006-09-20       Impact factor: 4.138

Review 7.  Proteasomes: multicatalytic proteinase complexes.

Authors:  A J Rivett
Journal:  Biochem J       Date:  1993-04-01       Impact factor: 3.857

Review 8.  [Proteasomes. Complex proteases lead to a new understanding of cellular regulation through proteolysis].

Authors:  W Hilt; D H Wolf
Journal:  Naturwissenschaften       Date:  1995-06

9.  Delineation of the subunit composition of human proteasomes using antisera against the major histocompatibility complex-encoded LMP2 and LMP7 subunits.

Authors:  S D Patel; J J Monaco; H O McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-04       Impact factor: 11.205

10.  Development of an in-vitro model system to investigate the mechanism of muscle protein catabolism induced by proteolysis-inducing factor.

Authors:  M C C Gomes-Marcondes; H J Smith; J C Cooper; M J Tisdale
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.